Protocol Information

If you are interested in learning more about this study, please call or email the contact person below

Title Study to Evaluate the Effect of Dapagliflozin on the Incidence of Worsening Heart Failure or Cardiovascular Death in Patients with Chronic Heart Failure with Reduced Ejection Fraction. D1699C00001
Description Study to Evaluate the Effect of Dapagliflozin on the Incidence of Worsening Heart Failure or Cardiovascular Death in Patients With Chronic Heart Failure

Study visits will be in downtown Buffalo or Williamsville
Objective This is an international, multicentre, parallel group, event-driven, randomized, double-blind, placebo-controlled study in patients with chronic heart failure with reduced ejection fraction (HFrEF), evaluating the effect of dapagliflozin 10 mg versus placebo, given once daily in addition to background regional standard of care therapy, for the prevention of cardiovascular (CV) death or reduction of heart failure (HF) events.

Keywords: Heart Failure, Reduced ejection fraction,
Principal Investigator CIMATO, THOMAS
Age Group Adult
Drugs Involved
Clinical Trials.gov http://www.clinicaltrials.gov/ct2/show/NCT03036124/
Status Open
Key Eligibility Age 18 or older
Heart failure with reduced ejection fraction
do NOT have Type 1 Diabetes
Disease Group Heart Diseases
Treatment dapagliflozin
Contact EILEEN DAETSCH
716-859-4641
daetsch@buffalo.edu